It is extremely important for BioCurex to sign another licensee to force Abbott to sprint toward the finish line. I have a feeling that when we see an announcement it will be just before the market opens to catch everyone off guard and give us a much needed shot in the arm. I would be content to know that Dr Moro is presenting at any upcoming diagnostic or oncology meetings in the near future. At least make an effort to convince the medical community that we are about to have Recaf commercialized. The lack of communication is cause for people to have doubts as to our progress. It is natural for any investor to be concerned, especially a biotech company. I call frequently, and I have no reason to doubt their enthusiasm about our future, but a majority of shareholders are really left out in the cold. If this company is to be successful at this stage of the game there should be monthly updates on their website.
News 
Market Data 
Discover 
AI
